logo

For the Inventor, By the Inventor

Greenboro, NC, United States of America

Anatoly A Mazurov

USPTO Granted Patents = 26 


 

Average Co-Inventor Count = 4.0

ph-index = 9

Forward Citations = 155(Granted Patents)


Location History:

  • Greenboro, NC (US) (2010)
  • Greensboro, NC (US) (2005 - 2017)

Company Filing History:

goldMedal23 out of 91 
 
Targacept, Inc.
 patents
silverMedal1 out of 2 
 
Attenua, Inc.
 patents
bronzeMedal2 out of 832,880 
Other
 patents

Years Active: 2005-2017

Loading Chart...
Loading Chart...
Loading Chart...
26 patents (USPTO):Explore Patents
1. 9580434 - Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes (2017-02-28),
2. 9173876 - Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide (2015-11-03),
3. 8921410 - Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes (2014-12-30),
4. 8901151 - Preparation and therapeutic applications of (2S, 3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide (2014-12-02),
5. 8859609 - Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes (2014-10-14),
6. 8846715 - (2S,3R)-N-(2((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide novel salt forms, and methods of use thereof (2014-09-30),
7. 8541447 - 3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereof (2013-09-24),
8. 8541446 - (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofurn-2-carboxamide, novel salt forms, and methods of use thereof (2013-09-24),
9. 8476296 - Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide (2013-07-02),
10. 8268860 - Sub-type selective amides of diazabicycloalkanes (2012-09-18),
11. 8198296 - Sub-type selective azabicycloalkane derivatives (2012-06-12),
12. 8158649 - 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof (2012-04-17),
13. 8143272 - 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof (2012-03-27),
14. 8124620 - 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof (2012-02-28),
15. 8124619 - 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof (2012-02-28),

Title: The Innovations of Anatoly A. Mazurov

Introduction

Anatoly A. Mazurov, located in Greensboro, NC, has made significant contributions to the field of pharmaceutical sciences. With a total of 26 patents, he has been at the forefront of innovations targeting neurons and neurotransmitter systems, particularly in the realm of central nervous system (CNS) disorders.

Latest Patents

Mazurov's latest inventions focus on nicotinic acetylcholine receptor subtype selective amides of diazabicycloalkanes. These compounds demonstrate an ability to selectively bind to neuronal nicotinic receptors of the α4β2 subtype within the CNS. The disclosed compounds and pharmaceutical compositions can be utilized to treat a variety of CNS disorders. Notably, these compounds alter the quantity of nicotinic cholinergic receptors in the brain, exhibit neuroprotective properties, and do so with minimal adverse effects, such as significant increases in blood pressure or gastrointestinal distress.

Another noted patent involves the preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide. This invention highlights compounds that can modulate the activity of neuronal nicotinic acetylcholine receptors. The processes for preparing these compounds and their pharmaceutical compositions further emphasize their potential in treating various CNS dysfunctions.

Career Highlights

Throughout his career, Anatoly A. Mazurov has been associated with Targacept, Inc., a company recognized for its innovative approaches in drug development focused on CNS disorders. His tenure there has reinforced his position as a reputable inventor and innovator in his field.

Collaborations

Mazurov has collaborated with notable professionals such as Lan Miao and Teresa Phillips, contributing to a dynamic research environment that fosters advancements in pharmacology and therapeutic applications. These partnerships have been instrumental in the successful development and patenting of his inventions.

Conclusion

Anatoly A. Mazurov continues to pave the way for breakthroughs in pharmacological treatments for CNS disorders through his inventive contributions. His expertise and dedication in the field have resulted in a substantial portfolio of patents that hold promise for enhancing medical treatments and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…